Back to News
Market Impact: 0.25
Disc Medicine Set To Report Phase 3 Bitopertin Results In Rare Blood Disorder; Stock Up
Source: Nasdaq
Healthcare & Biotech
Disc Medicine (IRON) is scheduled to release topline results today from the Phase 3 APOLLO trial of bitopertin in patients with erythropoietic protoporphyria (EPP), a rare inherited blood disorder. The excerpt does not report the results; the company is scheduled to discuss the findings during a corporate event.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
IRON0.00
More News
- Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints
- Disc Medicine stock soars: take profit or buy into strength?
- BMO raises Disc Medicine stock price target on positive trial data
- Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)
- Disc Medicine's Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission
- Capital One, General Motors are among the stocks reporting this week with momentum. Here are the others
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Options, Earnings Call Transcripts, AI Chat, Bookmarks & More
- AI Tools for Family Offices: A Stack by Decision Type